23 January 2012 - NovaDel Pharma Inc (OTCBB:NVDL), a US company developing oral spray formulations for a range of marketed pharmaceuticals, on Friday announced the termination of certain licence agreements with Par Pharmaceutical Companies Inc (NYSE:PRX) and Talon Therapeutics Inc (OTCBB:TLON) related to the development and commercialisation of the company's ondansetron HCl
oral spray product.
Total annual sales of Ondansetron HCl
Tablets and Ondansetron Orally Disintegrating Tablets, including brand and generic sales, are approximately $750 million and $350 million, respectively, in the U.
These products include metaxalone 400-mg tablets (Skelaxin); tramadol hydrochloride (HCL) and acetaminophen tablets (Ultracet); ondansetron HCl
orally disintegrating tablets (Zofran ODT); and mirtazapine orally disintegrating 45-mg tablets (RemeronSolTab).
is a generic version of the most widely used antiemetic drug for patients undergoing chemotherapy or surgery.